Endovia Health Sciences, Inc.

Name: Endovia Health Sciences, Inc. standardized financial statements, quarterly
Creator: Listed

EDVANYSECIK 1553788Consumer staplesFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026

Operating income−$2.0m, Q2 FY2026

Net income−$2.1m, Q2 FY2026

Endovia Health Sciences, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	5,144	2,688	1,541	1,047	982	(2,768)	68.6	(23.4)	393	(365)	4.2	0.0
Cost of revenue	$k	3,847	1,955	1,377	802	691	930	469	0.0	0.0	not reported	not reported	not reported
Gross profit	$k	1,297	733	164	244	291	(819)	25.5	(32.1)	(23.8)	47.3	1.8	0.0
Selling, general and administrative	$k	3,049	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Operating income	$k	(4,324)	(3,287)	(3,250)	(3,691)	(2,670)	(290)	(1,658)	(1,502)	(9,545)	(976)	(979)	(2,007)
Interest expense	$k	221	1,296	533	622	890	1,657	637	625	320	941	889	231
Income tax	$k	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$k	(5,670)	(5,994)	(4,671)	(5,327)	(4,720)	(9,039)	(3,650)	(8,493)	(9,886)	(3,205)	(2,136)	(2,055)
Diluted EPS	$ per share	(0.13)	not reported	not reported	not reported	not reported	not reported	(1.97)	not reported	not reported	not reported	(0.47)	not reported
Basic EPS	$ per share	(0.13)	not reported	not reported	not reported	not reported	not reported	(1.97)	not reported	not reported	not reported	(0.47)	not reported

Balance sheet

Cash and equivalents$242.7k, Q2 FY2026

Long-term debt$857, Q1 FY2026

Shareholders' equity−$15.7m, Q2 FY2026

Endovia Health Sciences, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	0.1	0.4	0.0	not reported	not reported	0.0	not reported	0.0	0.3	0.3	0.4	0.2
Current assets	$m	5.1	4.0	2.8	2.5	3.0	1.9	1.7	1.6	2.0	0.6	0.7	0.9
Total assets	$m	11.2	9.9	8.6	8.1	8.4	2.8	2.5	22.2	22.5	1.0	0.8	1.1
Current liabilities	$m	11.1	14.8	17.0	16.8	17.8	19.4	20.4	13.4	15.6	16.3	17.0	16.8
Total liabilities	$m	11.9	15.5	18.1	18.4	19.2	21.4	22.5	13.5	15.7	16.3	17.0	16.8
Long-term debt	$m	0.4	0.5	0.8	1.4	1.3	2.0	2.1	0.1	0.1	0.0	0.0	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Short-term borrowings	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	(0.7)	(5.6)	(9.5)	(10.4)	(10.8)	(18.6)	(20.0)	8.7	6.8	(15.3)	(16.2)	(15.7)

Cash flow

Operating cash flow−$1.1m, Q2 FY2026

Capital expenditure$0, Q4 FY2024

Endovia Health Sciences, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(1,982)	(1,685)	(1,308)	(2,430)	(2,645)	(920)	(808)	(551)	(2,470)	(991)	(930)	(1,092)
Capital expenditure	$k	0.0	1.5	0.0	not reported	not reported	0.0	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)3.06m, Q2 FY2026

Endovia Health Sciences, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	37.4	37.4	42.1	42.8	1.1	1.2	1.3	1.9	0.5	2.2	4.6	3.1

Shares outstanding: 6.41m at Aug 19, 2026, from the cover of the 10-Q filed Aug 19, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.